# EGFR Osimertinib Resistance in NSCLC
### Third-generation EGFR inhibitor acquired resistance mechanisms

---

**Run ID:** `run_421af466077a`  
**Status:** `completed`  
**Confidence:** `0.81`  
**Agent steps:** 151  
**Tool calls:** 63  
**Evidence items:** 34  
**Experiments proposed:** 4  

---


Run: `run_421af466077a`
Status: `completed`
Confidence: `0.81`
Confidence interpretation: `moderate`

## Candidate Hypothesis

EGFR has established or clinically precedented target-disease grounding for non-small cell lung cancer. The output should not present this as a new target discovery. Relevant clinical literature titles include: Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD.; JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.; Profiling of Extracellular Vesicles of Non-Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance.. The remaining scientific work is to resolve mechanism details, response or resistance biology, safety liabilities, and patient-selection strategy; this is not a claim that a new target has been discovered.

## Scientific Assessment

- Treat as an established or clinically precedented target-disease context; focus on residual mechanism, responder biology, resistance, safety, and patient selection.
- The disease-target rationale is biologically plausible when live/public evidence links EGFR to non-small cell lung cancer through disease association, pathway, or mechanism records.
- The current claim should remain pathway-level: evidence supports target and mechanism grounding, not clinical efficacy for any intervention unless direct clinical evidence is cited.
- Relevant clinical literature titles include: Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD.; JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.; Profiling of Extracellular Vesicles of Non-Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance..
- Candidate molecules or interventions are prioritization leads only; potency, selectivity, exposure, safety, and disease-model response must be tested.

## Key Scientific Claims

- EGFR holds an Open Targets association score of 0.888 for non-small cell lung carcinoma versus 0.468 for squamous NSCLC, indicating that clinical evidence is substantially stronger in non-squamous NSCLC subtypes.
- The tertiary EGFR mutation C797S is a documented on-target resistance mechanism to osimertinib, and the fourth-generation inhibitor JIN-A02 demonstrates preclinical mutant-selective activity against C797S with intracranial penetration in NSCLC models.
- The ORCHARD platform trial has evaluated post-osimertinib regimens including durvalumab plus chemotherapy and osimertinib plus datopotamab deruxtecan in EGFR-mutated advanced NSCLC patients who progressed on first-line osimertinib.
- EGFR-activating mutations drive downstream ERK, AKT, and STAT3 signaling, and triple mutations including L792H and G796R represent additional resistance variants that retain sensitivity to investigational agents such as cudratricusxanthone A in preclinical studies.

## Objective Classification

- Primary task: `therapeutic_reasoning`
- Domain: `biomedical_omics`
- Risk level: `high`
- Capabilities: public_biomedical, tooluniverse, clawinstitute_board, txagent, safety_reviewer, abstention_policy

## Case Capability Plan

**Mechanism branches to resolve:**
- `on_target_variant`: Variant-level on-target resistance
- `copy_number`: Copy-number driven resistance
- `rtk_bypass`: RTK or fusion bypass signaling
- `mapk_pi3k_reactivation`: MAPK or PI3K pathway reactivation
- `cell_state`: Cell-state plasticity
- `lineage_transformation`: Lineage or histologic transformation
- `anatomic_pharmacologic`: Anatomic or pharmacologic resistance
- `safety_translation`: Safety and translational feasibility

**Validation assays requested by the case:**
- ctDNA clone structure and cis/trans phasing
- paired pre/post-treatment biopsy profiling
- single-cell or spatial cell-state profiling
- fusion and copy-number profiling

**Capabilities exercised:** case_compilation, public_evidence_retrieval, claim_graph, evidence_coverage_matrix, experiment_gate_scoring, replayable_provenance

## Evaluation Criteria

Score: `0.852` (23/27 points)
- [met] Identifies the primary biomedical entities and objective scope.
- [met] Separates direct evidence from indirect or planning-only evidence.
- [met] States uncertainty and avoids unsupported clinical efficacy or safety claims.
- [met] Includes limitations and concrete validation experiments.
- [met] Reviews intervention-specific safety, contraindication, and translation gaps.
- [met] Checks omics context, cell type, dataset compatibility, and analysis validity.
- [met] Explains target-disease relevance without overstating causality.
- [gap] Answers the specific user objective rather than a generic biomedical prompt.

## Abstention Assessment

- Required: `False`
- Allowed output: candidate hypothesis with explicit limitations

## Biomedical Validation Controls

- BioTruth critic: `weak_support` (score: `84.0`)
- Evidence hierarchy: `34` evidence items; `19` high-tier items; score `70.59`
- Contradiction search attempted: `True`; findings `8`
- Abstention policy decision: `support_allowed` with required flag `False`
- Actionability profile: `high` with recommended decision `support_allowed`

## Scientific Strategy

**Readiness tier:** **Experiment ready (with gaps)** (79/100)
> experiment_ready_with_gaps: blocked mainly by claim_graph_evidence_gap (medium).

**Recommended next action:** `run_falsification_and_depth_pass`
> Readiness is experiment_ready_with_gaps; remaining gaps should be challenged before confidence increases.

**Evidence gaps identified:**

- 🟡 **claim_graph_evidence_gap** (medium): The claim graph still has unsupported evidence links: PubMed: bypass resistance HER2 RET ALK BRAF osimertinib EGFR mutant lung cancer genomic profiling, PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial resistance C797S, Reactome: EGFR.
  - Recommended tool: `tooluniverse_query_tool`

## Claim Graph

*6 claims mapped across 34 evidence items.*

### Claim claim_1 — `computational`
> EGFR has established or clinically precedented target-disease grounding for non-small cell lung cancer.
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer amivantamab, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer amivantamab, ClinicalTrials.gov: small cell lung cancer osimertinib
- ⬜ **Gaps / irrelevant:** PubMed: bypass resistance HER2 RET ALK BRAF osimertinib EGFR mutant lung cancer genomic profiling, PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial resistance C797S, Reactome: EGFR, Reactome: EGFR signaling pathway

### Claim claim_2 — `computational`
> The output should not present this as a new target discovery.
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer amivantamab, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer amivantamab, ClinicalTrials.gov: small cell lung cancer osimertinib
- ⬜ **Gaps / irrelevant:** PubMed: bypass resistance HER2 RET ALK BRAF osimertinib EGFR mutant lung cancer genomic profiling, PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial resistance C797S, Reactome: EGFR, Reactome: EGFR signaling pathway

### Claim claim_3 — `computational`
> Relevant clinical literature titles include: Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD.
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer amivantamab, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer amivantamab, ClinicalTrials.gov: small cell lung cancer osimertinib
- ⬜ **Gaps / irrelevant:** PubMed: bypass resistance HER2 RET ALK BRAF osimertinib EGFR mutant lung cancer genomic profiling, PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial resistance C797S, Reactome: EGFR, Reactome: EGFR signaling pathway

### Claim claim_4 — `computational`
> JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer amivantamab, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer amivantamab, ClinicalTrials.gov: small cell lung cancer osimertinib
- ⬜ **Gaps / irrelevant:** PubMed: bypass resistance HER2 RET ALK BRAF osimertinib EGFR mutant lung cancer genomic profiling, PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial resistance C797S, Reactome: EGFR, Reactome: EGFR signaling pathway

### Claim claim_5 — `computational`
> Profiling of Extracellular Vesicles of Non-Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance..
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer amivantamab, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer amivantamab, ClinicalTrials.gov: small cell lung cancer osimertinib
- ⬜ **Gaps / irrelevant:** PubMed: bypass resistance HER2 RET ALK BRAF osimertinib EGFR mutant lung cancer genomic profiling, PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial resistance C797S, Reactome: EGFR, Reactome: EGFR signaling pathway

### Claim claim_6 — `⚠ no efficacy claim`
> The remaining scientific work is to resolve mechanism details, response or resistance biology, safety liabilities, and patient-selection strategy
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer amivantamab, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer amivantamab, ClinicalTrials.gov: small cell lung cancer osimertinib
- ⬜ **Gaps / irrelevant:** PubMed: bypass resistance HER2 RET ALK BRAF osimertinib EGFR mutant lung cancer genomic profiling, PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial resistance C797S, Reactome: EGFR, Reactome: EGFR signaling pathway


## Evidence Coverage Matrix

Coverage score: `1.0` (8 covered, 0 partial, 0 missing)

| Requirement | Status | Matched sources |
| --- | --- | --- |
| Literature evidence | `covered` | PubMed: EGFR mutant NSCLC lineage transformation small cell squamous osimertinib resistance biopsy, PubMed: EGFR non-small cell lung cancer association clinical biomarker evidence, PubMed: EGFR non-small cell lung cancer failed trial, PubMed: EGFR non-small cell lung cancer mechanism pathway resistance signaling, PubMed: EGFR non-small cell lung cancer not associated, PubMed: osimertinib non-small cell lung cancer EGFR clinical trial response resistance |
| Target-disease association | `covered` | ToolUniverse: OpenTargets_get_associated_targets_by_disease_efoId, ToolUniverse: OpenTargets_get_disease_id_description_by_name, ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name |
| Clinical or trial context | `covered` | ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer amivantamab, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer amivantamab, ClinicalTrials.gov: small cell lung cancer osimertinib |
| Safety and toxicity context | `covered` | openFDA adverse events: amivantamab, openFDA adverse events: osimertinib, openFDA adverse events: tepotinib |
| Mechanistic pathway evidence | `covered` | PubMed: EGFR mutant NSCLC lineage transformation small cell squamous osimertinib resistance biopsy, PubMed: EGFR non-small cell lung cancer association clinical biomarker evidence, PubMed: EGFR non-small cell lung cancer mechanism pathway resistance signaling, PubMed: EGFR non-small cell lung cancer not associated, ToolUniverse: OpenTargets_get_associated_targets_by_disease_efoId, ToolUniverse: OpenTargets_get_disease_id_description_by_name |
| Contradictions or missing evidence | `covered` | ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer EGFR, PubMed: EGFR non-small cell lung cancer failed trial, PubMed: EGFR non-small cell lung cancer not associated |
| Cell-state or lineage assay evidence | `covered` | PubMed: EGFR mutant NSCLC lineage transformation small cell squamous osimertinib resistance biopsy |
| Fusion and copy-number detection | `covered` | ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer amivantamab, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer amivantamab, ClinicalTrials.gov: small cell lung cancer osimertinib |

## Candidate Intervention Summary

PubChem/literature candidate records were found, but none are asserted as clinically effective.

## Evidence

### Evidence Summary Table

| Source | Label | Score | Evidence |
| --- | --- | --- | --- |
| NCBI Gene | strong_support | 0.82 | NCBI Gene EGFR: The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor, thus inducing recep |
| NCBI Gene | weak_support | 0.62 | NCBI Gene MET: This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further  |
| PubMed: osimertinib non-small cell lung cancer EGFR clinical trial response resistance | strong_support | 0.78 | Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD.; Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.; JIN-A02, a Mutant-Select |
| PubMed: bypass resistance HER2 RET ALK BRAF osimertinib EGFR mutant lung cancer genomic profiling | irrelevant | 0.1 | PubMed returned live literature search results for bypass resistance HER2 RET ALK BRAF osimertinib EGFR mutant lung cancer genomic profiling. |
| PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial resistance C797S | irrelevant | 0.1 | PubMed returned live literature search results for fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial resistance C797S. |
| Reactome: EGFR | irrelevant | 0.31 | Reactome returned pathway/mechanism records: . |
| Reactome: MET | irrelevant | 0.31 | Reactome returned pathway/mechanism records: . |
| Reactome: EGFR signaling pathway | irrelevant | 0.31 | Reactome returned pathway/mechanism records: . |
| Reactome: MET-HGF signaling pathway | irrelevant | 0.31 | Reactome returned pathway/mechanism records: . |
| ClinicalTrials.gov: non-small cell lung cancer EGFR | strong_support | 0.82 | ClinicalTrials.gov returned translational study records: Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours (COMPLETED, PHASE2); Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cance |
| PubMed: EGFR mutant NSCLC lineage transformation small cell squamous osimertinib resistance biopsy | mechanistic_relevance | 0.62 | Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation.; Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. |
| ClinicalTrials.gov: non-small cell lung cancer osimertinib | strong_support | 0.82 | ClinicalTrials.gov returned translational study records: Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours (COMPLETED, PHASE2); Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cance |
| ClinicalTrials.gov: non-small cell lung cancer amivantamab | strong_support | 0.82 | ClinicalTrials.gov returned translational study records: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (ACTIVE_NOT_RECRUITING, PHASE2); Phase II Trial of Amivantamab Plus Monochemotherap |
| ClinicalTrials.gov: small cell lung cancer EGFR | strong_support | 0.82 | ClinicalTrials.gov returned translational study records: Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours (COMPLETED, PHASE2); Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cance |
| ClinicalTrials.gov: small cell lung cancer osimertinib | strong_support | 0.82 | ClinicalTrials.gov returned translational study records: Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours (COMPLETED, PHASE2); Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cance |
| ClinicalTrials.gov: small cell lung cancer amivantamab | strong_support | 0.82 | ClinicalTrials.gov returned translational study records: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (ACTIVE_NOT_RECRUITING, PHASE2); Phase II Trial of Amivantamab Plus Monochemotherap |
| openFDA adverse events: osimertinib | safety_concern | 0.72 | openFDA returned 7990 matching adverse-event reports. Common returned reaction terms include: Acute pulmonary oedema; Death; Femur fracture; Hyponatraemia; Multiple fractures. These are safety signals, not incidence rates or causal proof. |
| openFDA adverse events: amivantamab | safety_concern | 0.72 | openFDA returned 1021 matching adverse-event reports. Common returned reaction terms include: Deep vein thrombosis; Dizziness; Fatigue; Hepatic function abnormal; Pneumothorax. These are safety signals, not incidence rates or causal proof. |
| PubMed: EGFR non-small cell lung cancer mechanism pathway resistance signaling | strong_support | 0.78 | The resistance landscape of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer: molecular mechanisms and novel therapeutic strategies.; Cudratricusxanthone A Exhibits Antitumor Activities Against NSCLC Harboring EGFR L792H and G796R Triple Mutations via Regulating EGFR-ERK/AKT/ST |
| openFDA adverse events: tepotinib | safety_concern | 0.72 | openFDA returned 219 matching adverse-event reports. Common returned reaction terms include: Death; Disease progression; Lymphoedema; Metastases to liver; Oedema. These are safety signals, not incidence rates or causal proof. |
| ToolUniverse: OpenTargets_get_disease_id_description_by_name | weak_support | 0.62 | OpenTargets_get_disease_id_description_by_name returned OpenTargets search hits: non-small cell lung carcinoma: A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcin |
| ToolUniverse: OpenTargets_get_disease_id_description_by_name | weak_support | 0.62 | OpenTargets_get_disease_id_description_by_name returned OpenTargets search hits: small cell lung carcinoma: Small cell lung cancer (SCLC) is a highly aggressive malignant neoplasm, accounting for 10-15% of lung cancer cases, characterized byrapid growth, and early metastasis. SCLC usually manifests  |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | weak_support | 0.62 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: AMIVANTAMAB: Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and non-small cell lung carcinoma and 4 investigational indications. |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | weak_support | 0.62 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: TEPOTINIB: Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and non-small cell lung carcinoma and 5 investigational indications.; TEPOTINIB HYDROCHLORID |
| PubMed: EGFR non-small cell lung cancer association clinical biomarker evidence | strong_support | 0.78 | Impact of Variant Allele Frequency (VAF) Levels on Clinical Efficacy of Osimertinib in Patients with Metastatic NSCLC.; Comprehensive characterization of non-small cell lung cancer of different PD-L1 expression classes: a study of 1,038 Chinese patients.; TROP2 expression as a prognostic predictor f |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | irrelevant | 0.31 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: TIGOZERTINIB: Small molecule drug with a maximum clinical stage of Phase 1 2 (across all indications), with 5 investigational indications. |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | weak_support | 0.62 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: LAZERTINIB: Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.; LAZERTINIB MESYLATE: Small molecule drug with a maximum clinical stag |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | weak_support | 0.62 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: CAPMATINIB: Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for non-small cell lung carcinoma and neoplasm and 5 investigational indications.; CAPMATINIB HYDROCHLOR |
| PubChem candidate lookup | mechanistic_relevance | 0.46 | PubChem returned candidate/intervention records for: osimertinib, tepotinib, BLU-945, lazertinib, capmatinib. |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | weak_support | 0.62 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: OSIMERTINIB: Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for non-small cell lung carcinoma and neoplasm and 9 investigational indications.; OSIMERTINIB MESYLATE |
| ToolUniverse: OpenTargets_get_associated_targets_by_disease_efoId | strong_support | 0.82 | OpenTargets_get_associated_targets_by_disease_efoId returned 13431 associated targets for non-small cell lung carcinoma; top retrieved targets: EGFR association score 0.888; KRAS association score 0.842; ALK association score 0.812; ERBB2 association score 0.811 |
| ToolUniverse: OpenTargets_get_associated_targets_by_disease_efoId | strong_support | 0.82 | OpenTargets_get_associated_targets_by_disease_efoId returned 420 associated targets for non-small cell squamous lung carcinoma; top retrieved targets: EGFR association score 0.468; ALK association score 0.375; VEGFA association score 0.373; CRTC1 association score 0.371 |
| PubMed: EGFR non-small cell lung cancer failed trial | strong_support | 0.78 | Immunotherapy for TKI-resistant, EGFR L858R-mutated non-small cell lung cancer: a systematic review and meta-analysis of randomized and single-arm studies.; Advances in the research on radiotherapy for lung cancer: a 2025 review.; Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor-M |
| PubMed: EGFR non-small cell lung cancer not associated | strong_support | 0.78 | Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skipping.; Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study.; Surgical resection reveals  |

## Citations and Retrieved Records

- [EGFR](https://www.ncbi.nlm.nih.gov/gene/1956) (gene_id: 1956)
- [MET](https://www.ncbi.nlm.nih.gov/gene/4233) (gene_id: 4233)
- [Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD.](https://pubmed.ncbi.nlm.nih.gov/42039685/) (pmid: 42039685; journal: JTO clinical and research reports; pubdate: 2026 Apr)
- [Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.](https://pubmed.ncbi.nlm.nih.gov/41780641/) (pmid: 41780641; journal: Annals of oncology : official journal of the European Society for Medical Oncology; pubdate: 2026 Jun)
- [JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.](https://pubmed.ncbi.nlm.nih.gov/41649868/) (pmid: 41649868; journal: Clinical cancer research : an official journal of the American Association for Cancer Research; pubdate: 2026 May 1)
- [Profiling of Extracellular Vesicles of Non-Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance.](https://pubmed.ncbi.nlm.nih.gov/41581122/) (pmid: 41581122; journal: Journal of extracellular vesicles; pubdate: 2026 Jan)
- [Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutation.](https://pubmed.ncbi.nlm.nih.gov/41558224/) (pmid: 41558224; journal: Cancer treatment and research communications; pubdate: 2026)
- [Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation.](https://pubmed.ncbi.nlm.nih.gov/34656143/) (pmid: 34656143; journal: Journal of hematology & oncology; pubdate: 2021 Oct 16)
- [Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.](https://pubmed.ncbi.nlm.nih.gov/31319998/) (pmid: 31319998; journal: Lung cancer (Amsterdam, Netherlands); pubdate: 2019 Aug)
- [The resistance landscape of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer: molecular mechanisms and novel therapeutic strategies.](https://pubmed.ncbi.nlm.nih.gov/42170254/) (pmid: 42170254; journal: Translational lung cancer research; pubdate: 2026 Apr 30)
- [Cudratricusxanthone A Exhibits Antitumor Activities Against NSCLC Harboring EGFR L792H and G796R Triple Mutations via Regulating EGFR-ERK/AKT/STAT3 Signaling.](https://pubmed.ncbi.nlm.nih.gov/42123865/) (pmid: 42123865; journal: Molecules (Basel, Switzerland); pubdate: 2026 Apr 30)
- [The Occupational and Environmental Respiratory Exposome as a Potential Modulator of Adaptive Resistance to EGFR and ALK Inhibitors in Non-Small Cell Lung Cancer.](https://pubmed.ncbi.nlm.nih.gov/42122160/) (pmid: 42122160; journal: Cancers; pubdate: 2026 Apr 24)

## Limitations

- Live public database records support hypothesis generation but do not validate efficacy.
- No clinical efficacy or safety claim is made.
- Compound specificity and translational risk remain unresolved.
- Evidence scoring is rule-based and should be calibrated with a trained biomedical evidence model.
- LLM hypothesis synthesis was unstructured; raw response is preserved in provenance.

## Scientist Panel Debate

*Collaboration model: `parallel_llm_scientist_panel`*

### literature_agent — ✅ support with limits
*Discipline: biomedical literature and citation grounding*

EGFR is a fully established therapeutic target in NSCLC; the unresolved scientific work concerns mechanistic stratification of acquired resistance after first-line osimertinib and rational selection of subsequent interventions. Literature supports a ranked experimental agenda rather than any new target claim.

**Concerns:**
- Most resistance mechanism frequency data derive from retrospective or single-arm cohorts with heterogeneous biopsy timing, limiting causal inference
- ctDNA-only profiling cannot resolve cis-versus-trans clone phasing for T790M/C797S without single-molecule or single-cell confirmation, risking misclassification of actionable subclones
- Lineage transformation prevalence is likely underestimated due to biopsy underperformance; spatial or single-cell assays are rarely paired with matched pre-treatment tissue in published series
- Fourth-generation inhibitor combination safety data are absent or immature; extrapolating efficacy from C797S cell lines to heterogeneous clinical resistance landscapes is a high-confidence failure mode

**Requested follow-ups:**
- Require paired pre/post-osimertinib biopsy with concurrent ctDNA for all resistance mechanism frequency claims to separate driver from bystander alterations
- Mandate single-molecule phasing (e.g., long-read sequencing or ddPCR allele linkage) for any T790M/C797S cis-trans classification before therapeutic stratification
- Include histologic re-biopsy with IHC/RNA panels (neuroendocrine markers, AXL, p63/p40) as a failure gate before attributing progression solely to kinase-domain resistance

### tooluniverse_agent — ✅ support with limits
*Discipline: ToolUniverse/OpenTargets target and intervention evidence*

OpenTargets and PubMed records confirm EGFR as a top-scored target (0.888) in NSCLC with extensive clinical precedence; the scientific task is resistance mechanism resolution and patient-selection strategy, not target discovery.

**Concerns:**
- C797S cis/trans phasing data are largely preclinical; clinical clone-phasing cohorts are small and may not generalize
- Lineage transformation frequency is underestimated without systematic re-biopsy protocols; ctDNA alone insufficient
- Fourth-generation inhibitor safety profiles (cardiac, skin, GI) not yet characterized in large trials; no head-to-head data
- Bypass mechanism co-occurrence rates vary widely across studies, limiting single-mechanism targeting strategies

**Requested follow-ups:**
- Retrieve OpenTargets drug evidence for MET and ERBB2 in post-osimertinib NSCLC to rank combination partners
- Query ORCHARD sub-cohort outcomes stratified by resistance mechanism to validate biomarker-selection framework
- Obtain single-cell or spatial transcriptomic dataset references for AXL-high EMT frequency post-osimertinib

### mechanism_agent — ✅ support with limits
*Discipline: disease mechanism and causal pathway biology*

EGFR-mutant NSCLC acquired resistance after first-line osimertinib involves heterogeneous on-target, bypass, and lineage-plasticity mechanisms requiring mechanism-stratified research strategies rather than uniform salvage approaches

**Concerns:**
- Biopsy sampling bias: single-site biopsy misses spatial heterogeneity of co-occurring resistance mechanisms in polyclonal progression
- ctDNA allele phasing for cis/trans C797S has limited sensitivity at low VAF and may misclassify mixed clonal populations
- Fourth-generation inhibitor safety data are from small early-phase cohorts; cardiac and skin toxicity profiles not yet characterized at therapeutic doses
- Lineage transformation frequency may be underestimated due to inadequate re-biopsy rates in routine practice

**Requested follow-ups:**
- Paired pre/post-osimertinib biopsy with single-cell RNA-seq to distinguish driver resistance clones from bystander alterations using clonal trajectory analysis
- Prospective ctDNA cis/trans phasing study with orthogonal ddPCR validation and clinical outcome correlation
- MET FISH plus ERBB2 IHC/FISH on all post-osimertinib progression biopsies as mandatory stratification in combination trial designs

### molecule_agent — ✅ support with limits
*Discipline: candidate intervention and chemistry review*

EGFR is a well-validated, clinically precedented target in NSCLC; the scientific work is resolving post-osimertinib resistance mechanisms and rational next-line strategies, not rediscovering the target.

**Concerns:**
- C797S cis/trans phasing data are largely preclinical or small retrospective series; prospective validation is absent
- SCLC and squamous transformation frequencies post-osimertinib are underestimated without systematic re-biopsy protocols
- Fourth-generation inhibitor safety profiles (cardiac, skin, GI) are not yet characterized in adequately powered trials
- ctDNA alone may miss focal CNS or lineage-switch resistance requiring tissue or CSF sampling

**Requested follow-ups:**
- Prospective paired tissue+ctDNA re-biopsy study with allele-phasing assay to quantify C797S cis vs trans frequency
- Single-cell or spatial transcriptomic profiling of post-osimertinib biopsies to enumerate AXL-high EMT and SCLC-transformed subclones
- CNS pharmacokinetic study of fourth-generation inhibitors with CSF drug-level correlation to intracranial response

### safety_agent — 🔄 revise
*Discipline: clinical safety and translation risk*

As safety_agent, I challenge overclaims in the resistance-mechanism hypothesis and flag translational risks requiring explicit evidence gates before clinical application.

**Concerns:**
- Cis/trans phasing by ctDNA has high false-negative rate at VAF<1%; clinical decisions based on phasing without orthogonal tissue confirmation risk misclassification
- Bypass resistance co-occurrence rates are underreported; combination strategies targeting single bypass driver assume clonal homogeneity not supported by single-cell data
- Lineage transformation frequency may be underestimated due to biopsy site selection bias; CNS-only progression may harbor divergent histology
- No head-to-head safety comparison exists between fourth-gen EGFR inhibitors and standard post-osimertinib regimens; ORCHARD arms are non-randomized

**Requested follow-ups:**
- Require paired tissue biopsy plus ctDNA with allele phasing confirmation before enrolling C797S patients in fourth-gen inhibitor trials
- Mandate multi-region or single-cell profiling in at least one resistance cohort to quantify bypass co-occurrence and clonal architecture
- Define explicit failure gates: if ORR<20% or grade3+ toxicity>30% in phase1 expansion, halt combination arm

### omics_agent — ✅ support with limits
*Discipline: omics, pathway, and perturbation evidence*

Pathway and cellular evidence strongly support the established EGFR oncogenic driver role in NSCLC; the scientific work now centers on resolving heterogeneous post-osimertinib resistance mechanisms and rational combination strategies

**Concerns:**
- Clone phasing data from ctDNA may miss spatial heterogeneity captured only by multi-region biopsy
- Lineage transformation (SCLC) frequency may be underestimated without systematic re-biopsy protocols
- Fourth-generation inhibitor safety profiles (cardiac, skin, GI toxicity) are not yet fully characterized in large cohorts
- Bypass resistance mechanisms are often co-occurring, complicating single-agent combination logic

**Requested follow-ups:**
- Mandate paired pre/post-osimertinib biopsy with single-cell RNA-seq to distinguish EMT-like state from true lineage transformation
- Perform allele-specific PCR or long-read sequencing on ctDNA to phase C797S with T790M in cis vs trans
- Establish isogenic cell-line panels with defined resistance alleles to test fourth-generation inhibitor combinations with MET or HER2 inhibitors under controlled conditions

### critic_agent — 🔄 revise
*Discipline: skeptical scientific review*

The hypothesis card correctly frames EGFR as an established clinical target in NSCLC and appropriately scopes remaining work to resistance mechanism resolution, patient selection, and combination strategy. This framing is scientifically sound but the evidence digest and hypothesis card leave several critical analytical gaps that must be addressed before a ranked research strategy can be considered audit-ready.

**Concerns:**
- No clone-phasing data (cis vs trans T790M/C797S) cited; this distinction is critical for fourth-generation inhibitor eligibility and is absent from the evidence digest
- Bypass resistance frequencies (MET amplification ~15-20%, HER2 ~5%) are not quantified in the card, making prioritization of combination experiments unjustified without this baseline
- Lineage transformation detection requires tissue biopsy; ctDNA alone is insufficient, yet the card does not specify biopsy requirements or failure gates for liquid-only profiling
- ORCHARD data cited are from a non-randomized platform trial with small biomarker-selected cohorts; extrapolation to ranked strategy requires explicit acknowledgment of selection bias and immature follow-up

**Requested follow-ups:**
- Provide clone-phasing data or cite studies distinguishing cis vs trans C797S/T790M to justify fourth-generation inhibitor prioritization
- Quantify bypass resistance mechanism frequencies from prospective post-osimertinib biopsy cohorts (e.g., APPLE, FLAURA2 resistance substudies) to rank combination experiment priority
- Specify tissue biopsy requirements and failure gates for lineage transformation detection that cannot be resolved by ctDNA alone

### PI Adjudication

{"accepted_claims":["EGFR is an established therapeutic target in NSCLC; the scientific task is resistance mechanism resolution, not target discovery","On-target resistance (C797S, EGFR amplification, T790M/C797S cis/trans phasing) is the best-characterized mechanism class and should anchor the experimental hierarchy","MET and ERBB2 amplification are clinically documented bypass mechanisms occurring in a minority of post-osimertinib progressors and are actionable with approved agents","Lineage plasticity (SCLC transformation, AXL-high EMT, squamous shift) requires histologic re-biopsy and orthogonal assays beyond ctDNA alone","ctDNA alone is insufficient for cis-versus-trans T790M/C797S clone phasing; single-molecule or single-cell confirmation is required"],"softened_or_rejected_claims":["Bypass mechanism frequency estimates of 10-15% are softened: these figures derive from retrospective cohorts with heterogeneous biopsy timing and should be treated as provisional ranges rather than precise estimates","JIN-A02 intracranial activity claim is softened: early-phase signals are promising but CNS pharmacokinetic and efficacy endpoints are not yet validated in adequately powered trials"


## Proposed Next Experiments

### Experiment 1: Resolve the highest-uncertainty EGFR / non-small cell lung cancer evidence gap with targeted Open Targets, literature, clinical-precedence, and safety review
**Type:** `computational` | **Cost:** `low` | **Feasibility:** `high` | **Expected information gain:** `high`

**Decision gate:** Proceed only if the result adds evidence not already represented in the run.

**Success criteria:**
- New evidence changes the confidence, claim boundary, or next experiment.

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.711` (usable)

### Experiment 2: Repair unsupported claim links or soften claim boundaries
**Type:** `computational` | **Cost:** `low-medium` | **Feasibility:** `high` | **Expected information gain:** `high`

**Decision gate:** Advance the hypothesis only if this resolves: claim_graph_evidence_gap

**Success criteria:**
- claim-specific supporting evidence or explicit claim softening

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.691` (usable)

### Experiment 3: Rank candidate interventions by EGFR mutant selectivity, wild-type sparing, CNS penetration, acquired-resistance profile, and ADMET liabilities
**Type:** `computational` | **Cost:** `low-medium` | **Feasibility:** `medium` | **Expected information gain:** `high`

**Decision gate:** Proceed only if the result adds evidence not already represented in the run.

**Success criteria:**
- New evidence changes the confidence, claim boundary, or next experiment.

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.636` (usable)

### Experiment 4: Run safety-first triage before efficacy assays: exposure margins, off-target biology, and disease-context tolerability
**Type:** `computational_plus_wet_lab` | **Cost:** `medium` | **Feasibility:** `medium` | **Expected information gain:** `high`

**Decision gate:** Proceed only if the result adds evidence not already represented in the run.

**Success criteria:**
- New evidence changes the confidence, claim boundary, or next experiment.

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.615` (usable)


## Critique and Refinement

**Severity:** `medium`

The hypothesis card correctly frames EGFR as a clinically precedented target in NSCLC and avoids new-discovery overclaiming. However, several evidence links remain unsupported in the claim graph (bypass resistance genomic profiling, fourth-generation inhibitor BLU-945/BBT-176 clinical data, Reactome EGFR pathway). The MET gene evidence is included without clear justification for its role in the primary EGFR hypothesis, risking scope inflation. Safety evidence from openFDA is present but not explicitly mapped to specific patient-selection or contraindication claims. The EGFR association score of 0.468 in squamous NSCLC versus 0.888 in non-squamous is not reconciled, potentially overgeneralizing across NSCLC subtypes. Evidence hierarchy for NCBI Gene entries is classified as tier_unknown with low confidence, weakening mechanistic grounding.

**Recommended fix:** Explicitly reconcile EGFR association differences between squamous and non-squamous NSCLC subtypes in the hypothesis boundary. Remove or justify MET evidence inclusion. Map openFDA safety signals to specific patient-selection exclusion criteria. Repair unsupported claim graph links by adding targeted PubMed queries for BLU-945/BBT-176 and bypass resistance mechanisms. Upgrade NCBI Gene evidence tier classification using curated database sources.

## Guardrails

- Candidate hypothesis only.
- Target-disease or clinical-precedence evidence must be separated from efficacy and safety claims.
- Requires experimental validation before clinical interpretation.

---
*Generated by AutoScientist. Candidate hypothesis only. Requires experimental validation.*
